Model-Based Population Pharmacokinetic Analysis of Nivolumab in Patients with Solid Tumors

CPT: Pharmacometrics and Systems Pharmacology

Volumn 6, Issue 1, 2017, Pages 58-66

  Bajaj, G ^a   Wang, X ^a   Agrawal, S ^a   Gupta, M ^a   Roy, A ^a   Feng, Y ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LACTATE DEHYDROGENASE; NIVOLUMAB; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; PDCD1 PROTEIN, HUMAN; PROGRAMMED DEATH 1 RECEPTOR;

ADULT; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; ESTIMATED GLOMERULAR FILTRATION RATE; FEMALE; HUMAN; IMMUNOGENICITY; KARNOFSKY PERFORMANCE STATUS; MAJOR CLINICAL STUDY; MALE; PHARMACOKINETIC ASSAY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SOLID TUMOR; TUMOR VOLUME; ANTAGONISTS AND INHIBITORS; BIOLOGICAL MODEL; DOSE RESPONSE; METABOLISM; MULTICENTER STUDY (TOPIC); NEOPLASMS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); STATISTICS AND NUMERICAL DATA;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS, PHASE I AS TOPIC; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; MODELS, BIOLOGICAL; MULTICENTER STUDIES AS TOPIC; NEOPLASMS; PROGRAMMED CELL DEATH 1 RECEPTOR;

EID: 85010711805     PISSN: None     EISSN: 21638306     Source Type: Journal    
DOI: 10.1002/psp4.12143     Document Type: Article

References (37)

1. Sharpe, A.H., Wherry, E.J., Ahmed, R., &, Freeman, G.J., The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection. Nat Immunol. 8, 239-245 (2007).
2. Momtaz, P., &, Postow, M.A., Immunologic checkpoints in cancer therapy: focus on the programmed death-1 (PD-1) receptor pathway. Pharmgenomics Pers Med. 7, 357-365 (2014).
3. Ott, P.A., Hodi, F.S., &, Robert, C., CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients. Clin Cancer Res. 19, 5300-5309 (2013).
4. Jurado, J.O., et al,. Programmed death (PD)-1:PD-ligand 1/PD-ligand 2 pathway inhibits T cell effector functions during human tuberculosis. J Immunol. 181, 116-125 (2008).
5. Wang, C., et al,. In vitro characterization of the anti-PD-1 antibody nivolumab, BMS-936558, and in vivo toxicology in non-human primates. Cancer Immunol Res. 2, 846-856 (2014).
6. Iwai, Y., Ishida, M., Tanaka, Y., Okazaki, T., Honjo, T., &, Minato, N., Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci U S A. 99, 12293-12297 (2002).
7. Topalian, S.L., et al,. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 366, 2443-2454 (2012).
8. Hino, R., et al,. Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma. Cancer. 116, 1757-1766 (2010).
9. Shih, K., Arkenau, H.T., &, Infante, J.R., Clinical impact of checkpoint inhibitors as novel cancer therapies. Drugs. 74, 1993-2013 (2014).
10. Topalian, S.L., et al,. Survival, durable tumor remission, and long-Term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol. 32, 1020-1030 (2014).
11. Robert, C., et al,. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 372, 320-330 (2015).
12. Rizvi, N.A., et al,. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): A phase 2, single-Arm trial. Lancet Oncol. 16, 257-265 (2015).
13. Opdivo® [prescribing information]. May, 2016. Princeton, NJ: Bristol-Myers Squibb.
14. Wolchok, J.D., et al,. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med. 369, 122-133 (2013).
15. Ansell, S.M., et al,. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med. 372, 311-319 (2015).
16. Brahmer, J.R., et al,. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 366, 2455-2465 (2012).
17. Feng, Y., Bajaj, G., Wang, X., Agrawal, S., Gupta, M., &, Roy, A., Model-based analysis of nivolumab pharmacokinetics to support clinical pharmacology profiling in patients with solid tumors [abstract]. Clin Pharmacol Ther. 97, PI-071 (2015).
18. Wang, Y., Special considerations for modeling exposure-response relationships for biologics. Presented at the 117th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics, San Diego, CA, March 8, 2016.
19. Schwarz, G., Estimating the dimension of a model. Ann Stat. 6, 461-464 (1978).
20. Harrell, F.E., Jr., Regression modeling strategies: with applications to linear models, logistic regression, and survival analysis. New York: Springer; 2001.
21. Gastonguay, M., Full covariate models as an alternative to methods relying on statistical significance for inferences about covariate effects: A review of methodology and 42 case studies [abstract], Annual Meeting of the Population Approach Group in Europe. Athens, Greece, 2011, Abstract 2229.
22. Ma, C., et al,. Interconversion of three measures of performance status: An empirical analysis. Eur J Cancer. 46, 3175-3183 (2010).
23. Ramalingam, S.S., et al,. Phase I study of vorinostat in patients with advanced solid tumors and hepatic dysfunction: A National Cancer Institute Organ Dysfunction Working Group study. J Clin Oncol. 28, 4507-4512 (2010).
24. Stevens, L.A., et al,. Evaluation of the Chronic Kidney Disease Epidemiology Collaboration equation for estimating the glomerular filtration rate in multiple ethnicities. Kidney Int. 79, 555-562 (2011).
25. R Core Team. R: A language and environment for statistical computing. Vienna, Austria, R Foundation for Statistical Computing (http://www.R-project.org/) 2016.
26. Agrawal, S., et al,. Evaluation of immunogenicity of nivolumab monotherapy and its clinical relevance in patients with metastatic solid tumors. J Clin Pharmacol.; e-pub ahead of print 2016.
27. Bergstrand, M., Hooker, A.C., Wallin, J.E., &, Karlsson, M.O., Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models. AAPS J. 13, 143-151 (2011).
28. Evans, W.J., et al,. Cachexia: A new definition. Clin Nutr. 27, 793-799 (2008).
29. Fearon, K.C., Cancer cachexia: developing multimodal therapy for a multidimensional problem. Eur J Cancer. 44, 1124-1132 (2008).
30. McMillan, D.C., The systemic inflammation-based Glasgow Prognostic Score: A decade of experience in patients with cancer. Cancer Treat Rev. 39, 534-540 (2013).
31. Fearon, K.C., et al,. Influence of whole body protein turnover rate on resting energy expenditure in patients with cancer. Cancer Res. 48, 2590-2595 (1988).
32. Meibohm, B.,: Dose response: The confluence of disease, endpoints, pharmacology, modality and their impact. Presented at the 117th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics, San Diego, CA, March 8-12, 2016.
33. Miyamoto, Y., Hanna, D.L., Zhang, W., Baba, H., &, Lenz, H.J., Molecular pathways: cachexia signaling-A targeted approach to cancer treatment. Clin Cancer Res. 22, 3999-4004 (2016).
34. Feng, Y., Masson, E., Dai, D., Parker, S.M., Berman, D., &, Roy, A., Model-based clinical pharmacology profiling of ipilimumab in patients with advanced melanoma. Br J Clin Pharmacol. 78, 106-117 (2014).
35. Joshi, A., et al,. An overview of the pharmacokinetics and pharmacodynamics of efalizumab: A monoclonal antibody approved for use in psoriasis. J Clin Pharmacol. 46, 10-20 (2006).
36. Lobo, E.D., Hansen, R.J., &, Balthasar, J.P., Antibody pharmacokinetics and pharmacodynamics. J Pharm Sci. 93, 2645-2668 (2004).
37. Mager, D.E., &, Jusko, W.J., General pharmacokinetic model for drugs exhibiting target-mediated drug disposition. J Pharmacokinet Pharmacodyn. 28, 507-532 (2001).